Logo
x

Search

Subscribe Now

 AstraZeneca

Daiichi Sankyo and AstraZeneca Report the EC’s Approval of Enhertu for HER2 Low/Ultralow Metastatic Breast Cancer (MBC)

Daiichi Sankyo and AstraZeneca Report the EC’s Approval of Enhertu for HER2 Low/Ultralow Metastatic Breast Cancer (MBC)

  • April 4, 2025
BridgeBio Receives the MHLW’s Approval for Beyonttra (Acoramidis) for Transthyretin-Mediated Amyloidosis Cardiomyopathy (ATTR-CM)

BridgeBio Receives the MHLW’s Approval for Beyonttra (Acoramidis) for Transthyretin-Mediated Amyloidosis Cardiomyopathy (ATTR-CM)

  • March 28, 2025
Harbour BioMed & AstraZeneca Partner to Develop Multi-Specific Antibodies across Various Therapeutic Areas

Harbour BioMed & AstraZeneca Partner to Develop Multi-Specific Antibodies across Various Therapeutic Areas

  • March 24, 2025
Daiichi Sankyo Reports Interim Data of P-III (DESTINY-Gastric04) Study Evaluating Enhertu in HER2+ Metastatic Gastric Cancer Patients

Daiichi Sankyo Reports Interim Data of P-III (DESTINY-Gastric04) Study Evaluating Enhertu in HER2+ Metastatic Gastric Cancer Patie...

  • March 4, 2025
Enhancing Autoimmune Care: Caterina Brindicci from AstraZeneca in a Riveting Conversation with PharmaShots

Enhancing Autoimmune Care: Caterina Brindicci from AstraZeneca in a Riveting Conversation with PharmaShots

  • March 3, 2025
A Retrospective Analysis on Cardiac Amyloidosis: Mina Makar from AstraZeneca in an Illuminating Conversation with PharmaShots

A Retrospective Analysis on Cardiac Amyloidosis: Mina Makar from AstraZeneca in an Illuminating Conversation with PharmaShots

  • February 24, 2025
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2025 PharmaShots - All Rights Reserved.